Amneal launches first Mephyton generic
Amneal Pharmaceuticals announced on Tuesday the launch of Phytonadione Tablets, USP, 5 mg, the first AB-rated therapeutic equivalent for Mephyton.
The product is available in 100-ct bottles and is now shipping to wholesalers, distributors and direct to the trade.
“We are extremely pleased to bring the first generic alternative for Mephyton to market,” stated Andy Boyer, executive vice president of Commercial Operations for Amneal. “It’s always rewarding to provide the healthcare system with new generics that provide lower cost alternatives and open the door for further competition.”
Annual U.S. sales of the blood-clotting drug were $106 million, according to March 2018 IQVIA market data.
No comments found